CN106620474A - 养胃保健药及其制备方法 - Google Patents
养胃保健药及其制备方法 Download PDFInfo
- Publication number
- CN106620474A CN106620474A CN201611239229.6A CN201611239229A CN106620474A CN 106620474 A CN106620474 A CN 106620474A CN 201611239229 A CN201611239229 A CN 201611239229A CN 106620474 A CN106620474 A CN 106620474A
- Authority
- CN
- China
- Prior art keywords
- parts
- stomach
- nourishing health
- health medicine
- particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 74
- 230000036541 health Effects 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229920002261 Corn starch Polymers 0.000 claims abstract description 25
- 239000008120 corn starch Substances 0.000 claims abstract description 25
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 6
- 210000002784 stomach Anatomy 0.000 claims description 90
- 239000002245 particle Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 229940099112 cornstarch Drugs 0.000 claims description 24
- 235000019640 taste Nutrition 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 244000223014 Syzygium aromaticum Species 0.000 claims description 19
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 19
- 240000004510 Agastache rugosa Species 0.000 claims description 17
- 244000025254 Cannabis sativa Species 0.000 claims description 17
- 241000522254 Cassia Species 0.000 claims description 16
- 240000004307 Citrus medica Species 0.000 claims description 16
- 235000001938 Citrus medica Nutrition 0.000 claims description 16
- 235000002555 Citrus medica var sarcodactylis Nutrition 0.000 claims description 16
- 244000062241 Kaempferia galanga Species 0.000 claims description 16
- 235000013421 Kaempferia galanga Nutrition 0.000 claims description 16
- 239000008213 purified water Substances 0.000 claims description 14
- 235000020985 whole grains Nutrition 0.000 claims description 13
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 7
- 235000013339 cereals Nutrition 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- 229910000831 Steel Inorganic materials 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000011122 softwood Substances 0.000 claims description 5
- 239000010959 steel Substances 0.000 claims description 5
- 231100000987 absorbed dose Toxicity 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 208000024891 symptom Diseases 0.000 abstract description 20
- 206010047700 Vomiting Diseases 0.000 abstract description 14
- 230000035622 drinking Effects 0.000 abstract description 13
- 201000006549 dyspepsia Diseases 0.000 abstract description 13
- 206010000087 Abdominal pain upper Diseases 0.000 abstract description 12
- 206010028813 Nausea Diseases 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 8
- 230000008693 nausea Effects 0.000 abstract description 8
- 208000024798 heartburn Diseases 0.000 abstract description 7
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241001529821 Agastache Species 0.000 abstract 1
- 241000628997 Flos Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 206010020601 Hyperchlorhydria Diseases 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 18
- 210000001015 abdomen Anatomy 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 230000009471 action Effects 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 230000008673 vomiting Effects 0.000 description 11
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 10
- 208000023652 chronic gastritis Diseases 0.000 description 10
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 206010067171 Regurgitation Diseases 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 210000004051 gastric juice Anatomy 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 5
- 239000005770 Eugenol Substances 0.000 description 5
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229960002217 eugenol Drugs 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 229940055726 pantothenic acid Drugs 0.000 description 5
- 235000019161 pantothenic acid Nutrition 0.000 description 5
- 239000011713 pantothenic acid Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 206010000060 Abdominal distension Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000007107 Stomach Ulcer Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 208000000718 duodenal ulcer Diseases 0.000 description 4
- 201000005917 gastric ulcer Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000004916 vomit Anatomy 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010042220 Stress ulcer Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000000767 anti-ulcer Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 208000036495 Gastritis atrophic Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 241000244188 Ascaris suum Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 229930194248 Licoflavone Natural products 0.000 description 1
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 1
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 1
- 235000019510 Long pepper Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 241000722363 Piper Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 240000003455 Piper longum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 244000297179 Syringa vulgaris Species 0.000 description 1
- 235000004338 Syringa vulgaris Nutrition 0.000 description 1
- 241001078983 Tetradium ruticarpum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000003622 anti-hsv Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- JTZPPHUZZDKEOC-RBQAPOGLSA-A chembl2367706 Chemical compound O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 JTZPPHUZZDKEOC-RBQAPOGLSA-A 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- -1 for example Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 235000021268 hot food Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 150000002630 limonoids Chemical class 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中药技术领域,是一种养胃保健药及其制备方法,该养胃保健药包括荜茇、高良姜、陈皮、佛手、藿香、肉桂、丁香、甘草、食用碳酸氢钠、玉米淀粉。本发明的养胃保健药对胃酸、胃胀、胃痛、烧心、恶心、呕吐、消化不良、酒后难受等症状效果显著,标本兼顾,药食同源,能够为百姓提供一种安全、有效、经济、合理的养胃保健药品。
Description
技术领域
本发明涉及中药技术领域,是一种养胃保健药及其制备方法。
背景技术
《黄帝内经》有言:“脾胃者,仓廪之官,五味出焉!”脾胃为人体的中州之土,脾胃弱则全身失养,体虚受病。有些人看似底蕴深厚,其实脾胃也很脆弱,稍不留神就可能会出现脾胃功能失调,一直以来被胃部不适困扰的人很多,中医多以胃脘痛、痞满、吐酸、嘈杂、纳呆等术语来描述。其症状多表现为饭后饱胀、上腹部疼痛不适、嗳气、食欲减退、泛酸、烧心、呕吐、恶心或消瘦、贫血、腹泻等。中医认为本病的发生多与饮食相关,饮食生冷、油腻、辛辣,过食、少食,饮食不规律等均可引起本病。外感邪气、情志不遂、体质虚弱等亦能引起本病。本病病位主要在胃,与肝、脾密切相关。治法上当以理气和胃为基本原则,但须审症求因,审因论治。
西医理论把以上的症状称急性胃炎和慢性胃炎,急性胃炎病因有多种,主要有应激、理化性损伤和急性细菌感染。慢性胃炎的发生主要与幽门螺旋杆菌(Hp)感染有关,与自身免疫、胆汁反流等因素也有一定关系。急性胃炎要去除病因,积极治疗原发疾病和创伤,纠正其引起的病理生理紊乱。常用抑制胃酸分泌药物,如奥美拉唑肠溶胶囊、盐酸雷尼替丁胶囊。慢性胃炎也要去除病因,Hp相关性胃炎需进行根除Hp的治疗。而其他慢性胃炎尚无特效疗法,大多不能使胃炎逆转,因此主要是对症治疗。应用保护胃黏膜药物如硫糖铝、麦滋林-S等。
目前对于胃炎的治疗,中药作用较慢,症型较多,患者难以把握,效果均不肯定,如能改善症状即可为“良药”;西药副作用一般较大,患者不是很愿接受,治疗周期长达3-5月,治疗费用高,西医对慢性胃炎尚无特效疗法,一般主张无症状者无需进行治疗,若有症状才进行对症治疗。
发明内容
本发明提供了一种养胃保健药及其制备方法,克服了上述现有技术之不足,其能有效解决目前对于胃炎的治疗中药存在作用较慢、西药副作用较大的问题。
本发明的技术方案之一是通过以下措施来实现的:一种养胃保健药,原料按重量份数计包括荜茇1.4份至3.4份、高良姜1.4份至3.4份、陈皮1.4份至3.4份、佛手0.8份至2.8份、藿香0.8份至2.8份、肉桂0.8份至2.8份、丁香0.2份至2.2份、甘草0.2份至2.2份、食用碳酸氢钠79份至81份、玉米淀粉4份至6份。
下面是对上述发明技术方案之一的进一步优化或/和改进:
上述原料按重量份数计包括荜茇2.4份、高良姜2.4份、陈皮2.4份、佛手1.8份、藿香1.8份、肉桂1.8份、丁香1.2份、甘草1.2份、食用碳酸氢钠80份、玉米淀粉5份。
上述养胃保健药按下述方法得到:第一步,将荜茇、高良姜、陈皮、佛手、藿香、肉桂、丁香和甘草粉碎过100目筛后取筛下物混合均匀得到八味药混合物,钴-60辐照灭菌,然后将八味药混合物与食用碳酸氢钠混合均匀得到混合物;第二步,取玉米淀粉质量1.5倍的常温纯化水,将玉米淀粉分散在常温纯化水中并搅拌均匀,然后再向其中加入玉米淀粉质量2.5倍的煮沸的纯化水,边加边搅,搅匀成半透明的淀粉糊,待玉米糊的温度降至55℃至60℃时,向玉米糊中加入混合物并充分搅拌混合均匀,得到握之成团触压即散的软材;第三步,用14目至16目筛网进行制粒得到颗粒,然后将颗粒干燥至颗粒的含水量为2%至3%得到干燥颗粒;第四步,先整粒,再向整粒成均匀化的干燥颗粒中加入干燥颗粒重量0.5%至1%的硬脂酸镁并混合均匀,然后进行压片的养胃保健药。
上述第一步中,钴-60辐照灭菌时的吸收剂量≤6KGy,辐照的时间为24小时。
上述第三步中,将颗粒于干热风循环烘箱在60℃至70℃条件下烘干得到干燥颗粒。
上述第四步中,以14目不锈钢网整粒成均匀化的干燥颗粒。
本发明的技术方案之二是通过以下措施来实现的:一种养胃保健药的制备方法,按下述步骤进行:第一步,将荜茇、高良姜、陈皮、佛手、藿香、肉桂、丁香和甘草粉碎过100目筛后取筛下物混合均匀得到八味药混合物,钴-60辐照灭菌,然后将八味药混合物与食用碳酸氢钠混合均匀得到混合物;第二步,取玉米淀粉质量1.5倍的常温纯化水,将玉米淀粉分散在常温纯化水中并搅拌均匀,然后再向其中加入玉米淀粉质量2.5倍的煮沸的纯化水,边加边搅,搅匀成半透明的淀粉糊,待玉米糊的温度降至55℃至60℃时,向玉米糊中加入混合物并充分搅拌混合均匀,得到握之成团触压即散的软材;第三步,用14目至16目筛网进行制粒得到颗粒,然后将颗粒干燥至颗粒的含水量为2%至3%得到干燥颗粒;第四步,先整粒,再向整粒成均匀化的干燥颗粒中加入干燥颗粒重量0.5%至1%的硬脂酸镁并混合均匀,然后进行压片的养胃保健药。
下面是对上述发明技术方案之二的进一步优化或/和改进:
上述第一步中,钴-60辐照灭菌时的吸收剂量≤6KGy,辐照的时间为24小时。
上述第三步中,将颗粒于干热风循环烘箱在60℃至70℃条件下烘干得到干燥颗粒。
上述第四步中,以14目不锈钢网整粒成均匀化的干燥颗粒。
本发明的养胃保健药对胃酸、胃胀、胃痛、烧心、恶心、呕吐、消化不良、酒后难受等症状效果显著,标本兼顾,药食同源,能够为百姓提供一种安全、有效、经济、合理的养胃保健药品。
具体实施方式
本发明不受下述实施例的限制,可根据本发明的技术方案与实际情况来确定具体的实施方式。本发明中所提到各种化学试剂和化学用品如无特殊说明,均为现技术中公知公用的化学试剂和化学用品;本发明中的百分数如没有特殊说明,均为质量百分数;本发明中的水如没有特殊说明,为自来水或纯净水;本发明中的溶液若没有特殊说明,均为溶剂为水的水溶液,例如,盐酸溶液即为盐酸水溶液;本发明中的常温一般指15℃到25℃的温度,一般定义为25℃。
下面结合实施例对本发明作进一步描述:
实施例1,该养胃保健药,原料按重量份数计包括荜茇1.4份至3.4份、高良姜1.4份至3.4份、陈皮1.4份至3.4份、佛手0.8份至2.8份、藿香0.8份至2.8份、肉桂0.8份至2.8份、丁香0.2份至2.2份、甘草0.2份至2.2份、食用碳酸氢钠79份至81份、玉米淀粉4份至6份。
实施例2,该养胃保健药,原料按重量份数计包括荜茇1.4份或3.4份、高良姜1.4份或3.4份、陈皮1.4份或3.4份、佛手0.8份或2.8份、藿香0.8份或2.8份、肉桂0.8份或2.8份、丁香0.2份或2.2份、甘草0.2份或2.2份、食用碳酸氢钠79份或81份、玉米淀粉4份或6份。
实施例3,该养胃保健药,原料按重量份数计包括荜茇2.4份、高良姜2.4份、陈皮2.4份、佛手1.8份、藿香1.8份、肉桂1.8份、丁香1.2份、甘草1.2份、食用碳酸氢钠80份、玉米淀粉5份。
实施例4,作为上述实施例的优化,该养胃保健药按下述方法得到:第一步,将荜茇、高良姜、陈皮、佛手、藿香、肉桂、丁香和甘草粉碎过100目筛后取筛下物混合均匀得到八味药混合物,钴-60辐照灭菌,然后将八味药混合物与食用碳酸氢钠混合均匀得到混合物;第二步,取玉米淀粉质量1.5倍的常温纯化水,将玉米淀粉分散在常温纯化水中并搅拌均匀,然后再向其中加入玉米淀粉质量2.5倍的煮沸的纯化水,边加边搅,搅匀成半透明的淀粉糊,待玉米糊的温度降至55℃至60℃时,向玉米糊中加入混合物并充分搅拌混合均匀,得到握之成团触压即散的软材;第三步,用14目至16目筛网进行制粒得到颗粒,然后将颗粒干燥至颗粒的含水量为2%至3%得到干燥颗粒;第四步,先整粒,再向整粒成均匀化的干燥颗粒中加入干燥颗粒重量0.5%至1%的硬脂酸镁并混合均匀,然后进行压片的养胃保健药
实施例5,作为实施例4的优化,第一步中,钴-60辐照灭菌时的吸收剂量≤6KGy,辐照的时间为24小时。
实施例6,作为实施例4和实施例5的优化,第三步中,将颗粒于干热风循环烘箱在60℃至70℃条件下烘干得到干燥颗粒。
实施例7,作为实施例4、实施例5和实施例6的优化,第四步中,以14目不锈钢网整粒成均匀化的干燥颗粒。
本发明的药理如下:
1、荜茇
辛、热,归胃、大肠经,温中,散寒,下气,止痛。治心腹冷痛,呕吐吞酸,肠鸣泄泻,冷痢,阴疝,头痛,鼻渊,齿痛。
荜茇的药理作用:1、荜茇挥发油具有镇静、镇痛、解痛作用;2、荜茇果实乙酸乙酯提取物对肠管平滑肌有很强的松弛作用,荜茇油具有广谱抗菌作用,对金黄色葡萄球菌、痢疾杆菌、伤寒杆菌、结核杆蔺等均有抑制作用;3、荜茇乙醇提取物对实验性胃溃疡有显著保护作用,对胃液的量及胃液总酸度也有明显抑制作用。
、高良姜
味辛,性温。有温胃散寒、行气、消食止痛之功效。主治脘腹寒痛、胃寒吐泻、消积食滞、消化不良等症。《本草从新》载本品“暖胃散寒,消食醒酒,治胃脘冷痛。”
高良姜的药理作用:
1、对消化***的影响,(1)调节胃功能:其水煎剂能强烈抑制胃肠推进运动,但又可促进胃排空。高良姜、吴茱萸1:1混合液有抗大鼠应激性溃疡,抑制胃运动,降低胃张力,减少收缩幅度,抑制胃酸分泌等作用。(2)调节肠功能:其水煎剂有兴奋肠管的作用,能对抗阿托品、肾上腺素引起的肠活动,其作用为通过组胺样和抗肾上腺素样作用而兴奋肠管。高良姜又含抑制组胺所致肠收缩的物质,能使兔肠张力和收缩幅度明显抑制,表现有类似阿托品样的作用。(3)抗胃溃疡:其水提物能明显对抗水浸应激性溃疡,可预防致坏死物质所引起的胃黏膜急性损伤。(4)促进胃液分泌:其浸出液灌胃有刺激胃酸排出量增加的作用,在灌注后3小时内,总酸排出量为对照组的3倍,同时,动物呕吐增多,胃液中黏液增多。(5)抗腹泻:其水提物对蓖麻油和番泻叶引起的腹泻有明显的对抗作用。(6)利胆:其水提物十二指肠给药,有明显的利胆作用。
、抗炎镇痛
(1)抗炎:其水提物小鼠灌服能抑制耳廓肿胀、足跖肿胀及毛细血管通透性增高。镇痛:其水提物小鼠灌服能抑制扭体反应,延长对热痛刺激的反应。其抗炎镇痛作用可能与抑制***合成的释放有关。抗菌、抗真菌:其水煎剂对10种革兰阳性细菌有不同程度的抗菌作用。3种胡椒酚衍生物具有较强的抑制真菌作用。
、陈皮
陈皮性温,味辛、苦,入脾、肺经。具有理气健脾、燥湿化痰、行气的功效。
陈皮的药理作用:助消化:陈皮的苦味物质是以柠檬苷和苦味素为代表的“类柠檬苦素”,这种类柠檬苦素味平和,易溶解于水,有助于食物的消化。陈皮含有挥发油、橙皮甙、维生素B、C等成分,它所含的挥发油对胃肠道有温和刺激作用,可促进消化液的分泌,排除肠管内积气,增加食欲。
、佛手
辛温、味辛、苦、酸,归于肝、脾、胃、肺经。具有疏肝理气,和胃止痛、燥湿化痰的功效。
佛手的药理作用:1、佛手醇提取物对肠道平滑肌有明显的抑制作用。2、佛手还有抗应激、调节免疫、抗肿瘤等作用。
、藿香
藿香性味辛、微温,入脾、胃、肺经。芳香化浊,和中止呕,发表解暑。用于湿浊中阻,脘痞呕吐,暑湿表证,湿温初起,发热倦怠,胸闷不舒,寒湿闭暑,腹痛吐泻,鼻渊头痛。
藿香的药理作用:1、增强消化,藿香有调节胃肠功能,促进胃液分泌,增强消化力的作用。2、抗真菌,其水煎剂试管内有较强的抑制真菌作用和抗菌作用。
、肉桂
肉桂性大热,味辛、甘,温中健胃、暖腰膝、治腹冷、气胀的作用。
肉桂的药理作用:1、对中枢神经***的作用:桂皮醛以250-500 mg/kg灌胃,能减少小鼠自发活动,对抗***产生的过度活动;用小鼠压尾法或腹腔注射醋酸扭体法表明桂皮醛有镇痛作用;2、抗溃疡作用:肉桂水提物腹腔注射,可防止大鼠应激性溃疡,灌胃或腹腔注射也可抑制5-羟色胺引起的大鼠胃溃疡,抗溃疡作用不仅由於抑制胃液分泌,而且促进胃粘膜的血流量;3、抑菌作用:肉桂的***及乙醇浸出液对革兰氏阳性菌及真菌有抑菌作用。
、丁香
丁香味辛、性温,具有温中降逆、补肾助阳的作用。主治脘腹冷痛,呃逆、呕吐、泄泻、肾虚阳痿,腰膝酸冷,阴疽。
丁香的药理作用:1、对消化***的影响:(1)抗胃溃疡;可抑制大鼠实验性胃溃疡形成。丁香挥发油和丁香酚可使胃黏液分泌显著增加,而酸度不增加。丁香酚可能是抗溃疡的活性成分;(2)健胃:可缓解腹部胀气,增强消化能力,减轻恶心呕吐;(3)抑制肠兴奋:其水煎剂能抑制离体兔肠自发性收缩,并能对抗乙酰胆碱、组胺等对离体肠管的兴奋作用;(4)抗腹泻:其水提物和丁香酚能拮抗番泻叶或蓖麻油引起的大肠性腹泻与肠腔积液。2、醒酒:丁香花香气袭人,具有醒酒的作用。《本草纲目》载:“丁香杀酒毒”。清代诗人邹升恒在《丁香和韵》中也有句云:“傍檐结密人难折,拂座香多酒易醒。”3、抗病原体:丁香油和丁香酚有广谱的抗菌作用,丁香中的鞣花单宁有抗单纯疱疹病毒作用。其水煎剂或乙醇浸出液有广谱的抗真菌作用,或杀死作用。丁香酚对白色念珠菌和新型隐球菌有显著的杀灭作用。其水提物能杀死犬和猪蛔虫。丁香油的作用较水煎剂的作用强。丁香油、丁香酚和乙酰丁香酚对毛滴虫具有很强的杀死作用。
、甘草
性平;味甘;归心、脾、肺、胃经。补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于:脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
甘草的药理作用:1、除去甘草甜素的浸膏及甘草中黄酮甙类对大鼠实验性溃疡有明显保护作用。2、甘草制剂能促进胃部粘液形成和分泌,延长上皮细胞寿命,有抗炎活性,常用于慢性溃疡和十二指肠溃疡的治疗。3、甘草黄酮具有消炎、解痉和抗酸作用。
、食用碳酸氢钠
是一种弱碱性的物质,平时可以用来调理身体内部的内环境的,尤其是在调节肠道疾病方面的效果是比较显著的。碳酸氢钠能中和胃酸,溶解黏液,降低消化液的黏度,并加强胃肠的吸收,起到健胃、抑酸和增进食欲的作用,可以更好地促进身体内部代谢的快速进行。
中医学认为“胃喜温恶寒”,大多数的胃部不适与胃受凉有关,热性食材能保护胃气,维护正常的脾胃功能,本发明选取8种味辛性温的中药食材配合食用碳酸氢钠组成保健食品,起到温中健胃,醒脾理气,制酸止痛之功,主要用于胃酸、胃胀、胃痛、烧心、恶心、呕吐、消化不良等症状。急慢性胃炎、浅表性胃炎、萎缩性胃炎、饮酒后难受等有上述证候者。
根据本发明上述实施例得到的养胃保健药,其临床效果如下:
例1:患者张女士,66岁,腹痛腹满、烧心、恶心呕吐7年。行胃镜提示慢性萎缩性胃炎、反流性胃炎。服用法莫替丁2年,时好时坏。服用本发明的养胃保健药,一次5粒,一日3次。三天后,恶心呕吐、烧心症状明显好转;服用2周后腹痛腹满症状减轻;继续服用30天后症状消失恢复正常,坚持服用3月,胃镜复查提示胃黏膜充血消失,胃液澄清康复。
例2:患者刘女士,44岁,脘腹胀满、拒压,嗳腐吞酸、舌苔厚腻、恶心呕吐、3年。多次行胃镜均提示弥漫性浅表性胃炎。断断续续服用温胃舒冲剂2月,效果欠佳,服用本发明的养胃保健药,一次5粒,一日3次。7天后,脘腹胀满、嗳腐吞酸明显好转;继续服用二周后恶心呕吐减轻;坚持服用20天后胃腹无不适感觉,巩固服用2月后,胃镜检查提示胃炎康复。
例3:患者王女士,16岁,嗳气吞酸、恶心欲吐,喜按压。服用三九胃泰颗粒1周,稍有缓解,服用本发明的养胃保健药,一次5粒,一日2次。2天后,嗳气吞酸、恶心欲吐明显好转;继续服用1周后胃腹无不适感觉,食欲佳,消化好。
例4:患者董先生,49岁,饭后饱胀、泛酸、无规律性上腹痛,行胃镜提示慢性胃炎,口服奥美拉唑肠溶片、丽珠得乐3天,泛酸、腹痛症状有所缓解,饭后饱胀症状依旧存在,服用本发明的养胃保健药,一次5粒,一日3次,2周后诸症皆除,2月后胃镜复查提示慢性胃炎康复。
例5:患者赵先生,42岁,舌苔白腻、不思饮食、嗳腐酸臭,食后胃腹胀满。服用吗丁啉1周,欠佳。服用本发明的养胃保健药,一次5粒,一日3次。3天后,上述症状明显好转;继续服用1周后胃腹无不适感觉,食欲佳,消化好。
例6:患者杨女士,30岁,腹胀、腹痛、纳差、恶心、呕吐,大便稀溏。行胃镜提示慢性胃炎,服用理中丸1周,未见效果,服用本发明的养胃保健药,一次5粒,一日3次。7天后恶心呕吐减轻,纳差明显好转;坚持服用15天后大便正常,上述症状消失,继续服用1月,胃镜复查提示胃炎康复。
例7:患者宋先生,41岁,胃部隐痛、恶心两月有余,尤其酒后胃不适还会加剧,行胃镜提示胃底、胃体、胃角黏膜充血水肿,胃窦粘膜花斑样充血,诊断为胃炎,口服藿香冲剂、三九胃泰颗粒3天,效果不佳,服用本发明的养胃保健药,一次5粒,一日2次,2天后症状缓解,7天后症状消失,继续服用3周,行胃镜检查,胃部黏膜充血水肿消失。
例8:患者张女士,55岁,上腹部隐痛嗳气、反酸、烧灼感、食欲不振、恶心呕吐,在当地县医院口服雷尼替丁等药物治疗,病情有所好转,停药后复发,行胃镜提示胃底胃体黏膜充血水肿,诊断为慢性胃炎,服用本发明的养胃保健药,一次5粒,一日2次,4天后嗳气、反酸症状消失,2周后诸症皆除,继续服用3周,行胃镜检查,胃底胃体黏膜充血症状康复。
例9:患者李女士,72岁,腹痛腹胀、泛酸嗳气,不思饮食,行胃镜提示胃底、胃体、胃角黏膜充血水肿,黏液糊黄色浑浊,胃窦局部黏膜菲薄,诊断为浅表性胃炎并萎缩,胆汁反流。服用本发明的养胃保健药,一次5粒,一日2次,3天泛酸嗳气症状缓解,2周后诸症都消失,嘱继续服用3月,胃镜复查黏膜充血康复,黏液糊恢复澄清。
例10:患者刘先生,36岁,酒后恶心、呕吐,胃痛难耐,头痛欲裂。行胃镜提示急性胃炎。服用本发明的养胃保健药,一次5粒,一日3次。半天后恶心、呕吐,胃痛减轻;继续服用1天后头痛减轻;坚持服用3天,诸症状消失。
例11:患者郑先生,47岁,酒后呕吐,胃部恶心、纳差,头晕难以站立,服用本食品,一次5粒,一日3次。1天后,上述症候明显好转;继续服用2天后胃腹无不适感觉,食欲佳,头晕消失。
例12:患者刘先生,33岁,由于跑业务,应酬不断,逢酒必醉,往往酒后胃部难受,头痛欲裂,嘱其在饮酒前半小时服用本食品,一次5粒,酒后服5粒,后联系该患者,自述按照此法饮酒不醉,酒后不难受。
例13:患者周先生,52岁,饮约1斤高度白酒,恶心呕吐,胃中难受,送医抽血提示血液酒精含量220毫克/100毫升,给其服用本发明的养胃保健药8粒,2小时后再次抽血检测血液酒精含量107毫克/100毫升,4小时后抽血检测血液酒精含量40毫克/100毫升。正常情况下,酒精在人体内的代谢存在人体代谢半衰期,就是喝酒后3小时左右体内酒精含量下降一半,6小时后可能又下降余下的一半。由以上数据可见,本发明的养胃保健药有显著的加快酒精代谢的作用。
由上述临床实验效果可知,本发明的养胃保健药对胃酸、胃胀、胃痛、烧心、恶心、呕吐、消化不良、酒后难受等症状效果显著,标本兼顾,药食同源,能够为百姓提供一种安全、有效、经济、合理的养胃保健药品。
以上技术特征构成了本发明的实施例,其具有较强的适应性和实施效果,可根据实际需要增减非必要的技术特征,来满足不同情况的需求。
Claims (10)
1.一种养胃保健药,其特征在于原料按重量份数计包括荜茇1.4份至3.4份、高良姜1.4份至3.4份、陈皮1.4份至3.4份、佛手0.8份至2.8份、藿香0.8份至2.8份、肉桂0.8份至2.8份、丁香0.2份至2.2份、甘草0.2份至2.2份、食用碳酸氢钠79份至81份、玉米淀粉4份至6份。
2.根据权利要求1所述的养胃保健药,其特征在于原料按重量份数计包括荜茇2.4份、高良姜2.4份、陈皮2.4份、佛手1.8份、藿香1.8份、肉桂1.8份、丁香1.2份、甘草1.2份、食用碳酸氢钠80份、玉米淀粉5份。
3.根据权利要求1或2所述的养胃保健药,其特征在于按下述方法得到:第一步,将荜茇、高良姜、陈皮、佛手、藿香、肉桂、丁香和甘草粉碎过100目筛后取筛下物混合均匀得到八味药混合物,钴-60辐照灭菌,然后将八味药混合物与食用碳酸氢钠混合均匀得到混合物;第二步,取玉米淀粉质量1.5倍的常温纯化水,将玉米淀粉分散在常温纯化水中并搅拌均匀,然后再向其中加入玉米淀粉质量2.5倍的煮沸的纯化水,边加边搅,搅匀成半透明的淀粉糊,待玉米糊的温度降至55℃至60℃时,向玉米糊中加入混合物并充分搅拌混合均匀,得到握之成团触压即散的软材;第三步,用14目至16目筛网进行制粒得到颗粒,然后将颗粒干燥至颗粒的含水量为2%至3%得到干燥颗粒;第四步,先整粒,再向整粒成均匀化的干燥颗粒中加入干燥颗粒重量0.5%至1%的硬脂酸镁并混合均匀,然后进行压片的养胃保健药。
4.根据权利要求3所述的养胃保健药,其特征在于第一步中,钴-60辐照灭菌时的吸收剂量≤6KGy,辐照的时间为24小时。
5.根据权利要求3或4所述的养胃保健药,其特征在于第三步中,将颗粒于干热风循环烘箱在60℃至70℃条件下烘干得到干燥颗粒。
6.根据权利要求3或4或5所述的养胃保健药,其特征在于第四步中,以14目不锈钢网整粒成均匀化的干燥颗粒。
7.一种根据权利要求1或2所述的养胃保健药的制备方法,其特征在于按下述步骤进行:第一步,将荜茇、高良姜、陈皮、佛手、藿香、肉桂、丁香和甘草粉碎过100目筛后取筛下物混合均匀得到八味药混合物,钴-60辐照灭菌,然后将八味药混合物与食用碳酸氢钠混合均匀得到混合物;第二步,取玉米淀粉质量1.5倍的常温纯化水,将玉米淀粉分散在常温纯化水中并搅拌均匀,然后再向其中加入玉米淀粉质量2.5倍的煮沸的纯化水,边加边搅,搅匀成半透明的淀粉糊,待玉米糊的温度降至55℃至60℃时,向玉米糊中加入混合物并充分搅拌混合均匀,得到握之成团触压即散的软材;第三步,用14目至16目筛网进行制粒得到颗粒,然后将颗粒干燥至颗粒的含水量为2%至3%得到干燥颗粒;第四步,先整粒,再向整粒成均匀化的干燥颗粒中加入干燥颗粒重量0.5%至1%的硬脂酸镁并混合均匀,然后进行压片的养胃保健药。
8.根据权利要求7所述的养胃保健药的制备方法,其特征在于第一步中,钴-60辐照灭菌时的吸收剂量≤6KGy,辐照的时间为24小时。
9.根据权利要求7或8所述的养胃保健药的制备方法,其特征在于第三步中,将颗粒于干热风循环烘箱在60℃至70℃条件下烘干得到干燥颗粒。
10.根据权利要求7或8或9所述的养胃保健药的制备方法,其特征在于第四步中,以14目不锈钢网整粒成均匀化的干燥颗粒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611239229.6A CN106620474B (zh) | 2016-12-28 | 2016-12-28 | 养胃保健药及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611239229.6A CN106620474B (zh) | 2016-12-28 | 2016-12-28 | 养胃保健药及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106620474A true CN106620474A (zh) | 2017-05-10 |
CN106620474B CN106620474B (zh) | 2020-03-24 |
Family
ID=58835316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611239229.6A Active CN106620474B (zh) | 2016-12-28 | 2016-12-28 | 养胃保健药及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106620474B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3115679B1 (fr) * | 2020-11-02 | 2023-10-27 | Jean Angelidis | Composition naturelle pour traitement gastrique, notamment pour le traitement d’ulcères gastriques, Procédé de fabrication associé et Application aux équidés |
-
2016
- 2016-12-28 CN CN201611239229.6A patent/CN106620474B/zh active Active
Non-Patent Citations (1)
Title |
---|
夏昌隆: "《医学制剂质量标准及起草说明》", 31 May 2002, 新疆科技卫生出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN106620474B (zh) | 2020-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102048933B (zh) | 一种治疗小儿腹泻的中药组合物及其制备方法 | |
CN102068707B (zh) | 一种b超使用的中药助影剂及其制备方法 | |
CN105768055A (zh) | 一种用于调理肠道的营养制剂及其制备方法 | |
CN104013756B (zh) | 一种防治腹泻的中药组合物及其用途 | |
CN103301267B (zh) | 一种治疗高血压和/或动脉粥样硬化的中药组合物及应用 | |
CN103977078A (zh) | 一种治疗人痢疾病的中药制剂及其生产方法 | |
CN1660387A (zh) | 调理人体内脏各器官机能平衡的保健制剂及其制备方法 | |
CN104888174A (zh) | 一种治疗脾胃虚寒型消化性溃疡的药物制剂及其制备方法 | |
CN106620474A (zh) | 养胃保健药及其制备方法 | |
CN105168522A (zh) | 医治腹胀的药剂及制法 | |
CN103040975B (zh) | 一种用于护理治疗小儿腹泻的中药组合物 | |
CN104491364B (zh) | 一种治疗慢性淋巴细胞性甲状腺炎的药丸及制备方法 | |
CN103690771B (zh) | 用于治疗羔羊大肠杆菌病的药物及其制备方法 | |
CN106214977A (zh) | 一种治疗噎膈的中药组合物 | |
KR20070016473A (ko) | 애견용 투명 한방 탕제 및 애견용 투명 한방 탕제의 제조방법 | |
CN106474421B (zh) | 一种治疗结直肠癌的中药组合物及其应用 | |
CN106860813A (zh) | 治胃病的中药组合物、其提取物、制备方法和含其的药剂 | |
CN105031330A (zh) | 一种治疗疝气的中药组合物及制法 | |
CN104940739A (zh) | 治疗胆道蛔虫症的中药组合物 | |
CN104107358A (zh) | 一种用于止咳化痰的药丸及其制备方法 | |
CN114984179A (zh) | 一种治疗或预防米格列奈不良反应的组合物及其制备方法和应用 | |
CN109674977A (zh) | 用于治疗胃肠类疾病的中药组合物、应用和复方制剂 | |
CN103055271A (zh) | 一种用于治疗慢性胃炎的药物及制备方法 | |
CN106072096A (zh) | 慢性萎缩性胃炎伴糜烂食疗方 | |
CN109806358A (zh) | 一种十味健脾消食散及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200226 Address after: 830000, No. 284, gymnasium Road, Tianshan District, the Xinjiang Uygur Autonomous Region, Urumqi 2-3-701 Applicant after: Wang Guodong Address before: 830000, No. 284, gymnasium Road, Tianshan District, the Xinjiang Uygur Autonomous Region, Urumqi 2-3-701 Applicant before: Li Wei |
|
GR01 | Patent grant | ||
GR01 | Patent grant |